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Synthesis and biological evaluation of cyclic derivatives of 
combretastatin A-4 containing group 14 elements 
Víctor Blasco,a  Juan Murga,b  Eva Falomir, *b Miguel Carda,b  Santiago Royo,b Ana C. Cuñat,*a  Juan 
F. Sanz-Cerveraa  and  J. Alberto Marcoa 
Several tricyclic compounds inspired in the structure of combretastatin A-4 and bearing group 14 
elements have been synthesized by homocoupling of lithiated aryl fragments followed by ring-closing 
metathesis. These tricyclic compounds and their diolefin precursors were evaluated for their 
antiproliferative action on the tumor cell lines HT-29, MCF-7, HeLa and A-549 and on the non-tumor 
cell line HEK-293. In addition, their effects on the cell cycle were also measured. The tricyclic 
compounds show antiproliferative activity similar to combretastatin A-4, even though they are not so 
active in arresting cell cycle. However, some diolefin precursors are able to cause accumulation of cells 
in the G2/M phase in a higher percentage than combretastatin A-4 itself. Inhibition of endothelial tube 
formation and VEGFR-2 phosphorylation of some selected compounds are comparable to that of 
combretastatin A-4, particularly those of tin-containing compounds 17c and 24c, whose actions 
exceed those of sorafenib, a clinically used VEGFR-2 inhibitor. 
 
Introduction  
Evolution of life on Earth has originated a myriad of organic 
compounds from plants and microorganisms. These natural products 
display a wide variety of structures, many of them endowed with a 
plethora of organic functions resulting from countless biosynthetic 
pathways. Since ancient times humankind has used these 
compounds, particularly those extracted from plants, as drugs to 
cure various diseases.1 Furthermore, natural products have an ample 
range of binding groups that allow them to interact within various 
biological targets in an optimal way.2 The vast chemical diversity and 
novel mechanisms of action of natural products explain the pivotal 
role they have been playing in many drug development 
programmes.3 
Cancer is a group of diseases characterized by the uncontrolled 
growth and spread of abnormal cells. Cancer is caused by both 
external and internal factors that may act together or in sequence to 
initiate or promote carcinogenesis. Chemotherapy with cytotoxic 
drugs is the main treatment for certain types of cancer. Among the 
anti-cancer drugs approved in the period from 1940-2002, 
approximately 54% were derived from natural products or 
derivatives thereof.4 Developments in synthetic chemistry have 
allowed the modification of natural products and the synthesis of 
new chemical structures endowed with new and better 
pharmacological properties. The incorporation of various types of 
metal atoms into synthetic molecules, for instance, has allowed the 
preparation of new pharmacologically valuable drugs, with cis-
platinum and its derivatives being archetypal examples.5 Our interest 
on natural product analogues6 has led us to prepare several of such 
analogues and to investigate their activity as antiproliferative 
agents.7 Combretastatin A-4 (CoA4, see structure I in Fig. 1), for 
instance, is a compound that belongs, like the well-known 
resveratrol, to the stilbene class of natural products.8 Several 
compounds of the combretastatin family have acquired an 
outstanding status in the last years and found utility in various 
pharmacological applications, most particularly as anticancer 
agents.9 Preclinical and clinical developments over the last decade 
have been rapidly accelerating for drugs such as I, most particularly 
in the form of its more water-soluble phosphate prodrug CA-4P 
(structure II, Fig. 1).10 These encouraging developments have 
stimulated a variety of efforts devoted to the synthesis and biological 
evaluation of numerous structurally modified combretastatin 
derivatives and analogues.11 
 
 
Fig. 1  Structures of combretastatin A-4 (I) and its phosphate prodrug 
(II) 
a. Departamento de Química Orgánica, Universidad de Valencia, E-46100 Burjassot 
Valencia, Spain 
b. Departamento de Química Inorgánica y Orgánica, Universidad Jaume I, E-12071
Castellón, Spain 
Electronic Supplementary Information (ESI) available: [details of any supplementary 
information available should be included here]. See DOI: 10.1039/x0xx00000x 
ARTICLE Journal Name 
2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
Very recently, we have published several reports on the biological 
properties of several CoA4 analogues with cytotoxic activity.12 One 
of the potential drawbacks of I and derivatives is the fact that they 
are prone to cis-trans isomerization induced by light or traces of acid 
impurities. This is undesirable because the trans isomers are 
practically devoid of biological activity.13 We thus conceived the 
synthesis and biological evaluation of a family of CoA4 analogues 
such as III (Fig. 2) in which the presence of an additional cycle 
prevents the possibility of cis-trans isomerization.14 The atom Z may 
belong in principle to any element of groups 14-16 in the periodic 
system but we have selected for the initial phase several elements of 
group 14 (Si, Ge, Sn).15 It is expected that the differences in C−Z bond 
lengths, according to the nature of Z, will be reflected in differences 
in the dihedral angle between the two benzene rings, a feature which 
has been found to have an influence on the biological activity.16 
 
Fig. 2 General structure of tricyclic derivatives of CoA4 
Results and discussion  
Chemistry 
 
The initial synthetic concept towards compounds of type III is that 
depicted in Scheme 1. Thus, cyclic compounds such as III would be 
obtained by reaction of the electrophilic reagent ZHal2 (Z = atom 
from group 14, Hal = halogen) with the dilithium derivative IV to be 
prepared in turn from dibromo derivative V. For the synthesis of the 
latter compound we envisaged a Z-selective Wittig olefination, for 
which there is a close precedent.17 The precursors would be the ylide 
generated from phosphonium salt 1 and the protected aldehyde 2 
generated from the commercially available 3. 
 
Scheme 1 Retrosynthetic analysis 
Scheme 2 shows the results of the synthetic work. Aldehyde 3 was 
protected as its allyl and tert-butyldimethylsilyl (TBS) derivatives, 4 
(R = allyl) and 5 (R = TBS), respectively. These were then allowed to 
react with the known phosphonium salt 1 in the presence of 
potassium tert-butoxide to yield the cis stilbene derivatives 6 and 7, 
respectively, with excellent stereoselectivity (see Experimental for 
details on reaction conditions and yields). 
 
Scheme 2 Synthesis of dibromo derivatives 6-9. Abbreviations: TBS, 
tert-butyldimethylsilyl; TBAF, tetra-n-butylammonium fluoride; 
MOM, methoxymethyl; DIPEA, N,N-diisopropyl ethylamine. 
The following step in the sequence proved disappointing. All 
attempts to cyclize compounds 6 and 7 by means of bromine-lithium 
interchange followed by treatment with the three electrophilic 
reagents indicated below met with failure (Scheme 3). In the case of 
compound 6 extensive decomposition took place whereas in the case 
of 7, the product of reductive dehalogenation was isolated in low 
yield. Its structure was confirmed by the fact that desilylation yielded 
CoA4. A second side product isolated in low yield seemed to be the 
result of lithiation followed by a retro-Brook-type silyl migration.18 
Conjecturing that the nature or else the presence of the protecting 
group R might be the cause of the failures, we made further attempts 
with the unprotected compound 8 and with the MOM-protected 
derivative 9, prepared as shown in Scheme 2. However, we were not 
successful with any one of these two compounds, either. With both 
of them, products of reductive dehalogenation were obtained in low 
yield. In the case of 8, the dehalogenation product was CoA4 itself. 
While disappointing, these results confirmed that at least bromine-













OR1: n-BuLi, 78ºC, THF




Scheme 3 Attempts to prepare tricyclic derivatives 
After this lack of success, we reasoned that the failure in the 
cyclization was possibly due to a too slow reaction of the electrophile 
ZHal2 with the C−Li bonds in the lithiated intermediate IV (see 
Scheme 1). Since structurally close organolithium compounds with a 
lower substitution degree in the rings reacted in the expected way,17 
these negative results may be due to both C−Li bonds in IV being 
sterically hindered (ortho disubstitution). In view of this, we decided 
to revert the order of formation of bonds of the cyclic system. The 
two C−Z bonds would now be formed first by means of an 
intermolecular process, followed by subsequent creation of the C=C 
bond through an intramolecular olefin metathesis. This new type of 
strategy, which has precedent,19 is depicted in Scheme 4. Thus, III 
should be obtained by means of ring-closing metathesis (RCM) of 
diolefin VI, to be in turn prepared through sequential coupling of the 
electrophile ZHal2 with the two indicated organolithium reagents. 
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The latter would be synthesized by means of bromine-lithium 
interchange in bromoarenes VII and VIII. 
 
Scheme 4 Retrosynthetic analysis based on RCM 
Compound 10 was synthesized by means of Wittig methylenation 
of the commercially available 2-bromo-3,4,5-trimethoxy-
benzaldehyde. Likewise, 11 was prepared from aldehyde 3 through 
sequential tritylation (Trt = trityl) and Wittig methylenation (Scheme 
5). 
 
Scheme 5. Structure of 10 and synthesis of 11 
Bromoarene 10 was then converted into the corresponding 
organolithium derivative 12 (n-BuLi, THF, −78°C), and the laOer was 
treated with one equivalent of the appropriate electrophilic reagent 
ZHal2 and stirred for 15 min. at the same temperature (Scheme 6). 
Then the bath was allowed to reach room temperature and further 
stirred for 12 h. Subsequently, the reaction mixture was treated with 
one equivalent of the organolithium derivative 13 (generated from 
11) and further stirred for 12 h at room temperature. 
  
 
Scheme 6 Attempts to prepare 14 
Unfortunately, none of the desired heterocoupling compound 14 
was obtained. Products of reductive dehalogenation were isolated in 
low yield, together with products of homocoupling (see below). We 
then tried an inversion of the order of the steps: organolithium 13 
was allowed to react with the electrophile ZHal2 followed by addition 
of 12. The same lack of success was observed. As commented, the 
reaction mixtures above (Scheme 6) were shown to contain products 
of homocoupling. In view of this, we considered the possibility of 
preparing symmetric compounds such as 15 (Scheme 7), which still 
display the pharmacologically important vic-trimethoxyphenyl 
fragment. Indeed, compounds 15 (Z = SiMe2, GeMe2, SnMe2) were 
obtained in two steps from 10 under the aforementioned reaction 
conditions.20 Subsequently, ring-closing olefin metathesis to 
combretastatin-type compounds 16 (Z = SiMe2, GeMe2, SnMe2) was 
performed by means of heating at reflux a solution of 15 and a 
second-generation Hoveyda-Grubbs ruthenium catalyst21 in dry, 
deoxygenated toluene. The RCM step took place with good yields for 
Z = SiMe2 and GeMe2 but with a low yield for Z = SnMe2 (see 
Experimental for details on reaction conditions and yields). 
 
Scheme 7 Synthesis of tricyclic derivatives 
In order to expand the range of cyclic combretastatin-like 
structures for biological investigation, we further performed the 
same reaction sequence starting with three other aromatic 
aldehydes 17-19 (Scheme 8). 
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26a Z = SiMe2
26b Z = GeMe2
27a Z = SiMe2
27b Z = GeMe2
27c Z = SnMe2
28a Z = SiMe2
28b Z = GeMe2






23a Z = SiMe2
23b Z = GeMe2







25a Z = SiMe2
25b Z = GeMe2











24a Z = SiMe2
24b Z = GeMe2
24c Z = SnMe2
 
Scheme 8 Synthesis of tricyclic derivatives 
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Thus, the cyclic, combretastatin-like compounds 26-28 were 
obtained (see Experimental for details on reaction conditions and 
yields). As in the previous case, the RCM step gave good yields when 
Z = SiMe2, GeMe2 but low yields when Z = SnMe2 (indeed, 0% for 26c). 
In these cases, extrusion of the tin fragment took place with 
formation of phenantrene derivatives. This behavior has precedent 
in similar systems with group 15 elements.19c 
Biological results 
Effect on the inhibition of cell proliferation 
The inhibition of cell proliferation of CoA4 and its tricyclic 
derivatives was measured by means of their IC50 values towards the 
tumor cell lines HT-29 (human colon adenocarcinoma), MCF-7 
(breast adenocarcinoma), HeLa (human epithelioid cervix 
carcinoma), A-549 (human lung adenocarcinoma) and in non-tumor 
cell line HEK-293 (human embryonic kidney). In addition to the 
compounds indicated in schemes 7 and 8, the acyclic geometrical 
isomers 29 and 3022 drawn in Scheme 9 were also evaluated for 
comparison purposes. 
 
Scheme 9 Structures of (Z) and (E)-1,2-bis(3,4,5-trimethoxyphenyl) 
ethylene 
IC50 values are presented in Table 1 along with the calculated 
selectivity indexes (SI) obtained by dividing the IC50 values of the non-
tumor cell line (HEK-293) by those of the corresponding tumor cell 
line. The higher the SI index of the compound, the higher its 
therapeutic safety margin. 
Most of the cyclic derivatives show antiproliferative activity in the 
low micromolar range although they are not as active as CoA4. The 
most active compounds are 16a-c, 26a and 27a-c, particularly on the 
HT-29 and MCF-7 lines. Fluorinated compounds 28a-c exhibited 
much lower antiproliferative actions. As regards selectivity indexes, 
the best compounds are 16b, 27c and 28b with SI values well above 
1. Furthermore, when the IC50 values of 29 and 30 are compared, it 
is observed that the trans 30 isomer is much less active than the cis 
isomer 29. This confirms previous observations that a cis 
configuration is needed in order to achieve a noticeable 
antiproliferative acivity.14 Besides, IC50 values of the acyclic 
compound 29 are quite similar to those of tricyclic analogues 16a-c, 
which means that the presence of the bridging atom does not 
perturb the antiproliferative action. 
The acyclic precursor compounds 23a-c, 24a-c and 25a-c were also 
evaluated. Their IC50 values were also in the µM range, although they 
were slightly higher than those of their tricyclic analogues and their 
SI values were lower than their tricyclic derivatives. In this sense, it is 
worth to mention that compound 24c is that having the higher 
selectivity index. The higher antiproliferative activity of the tricyclic 
derivatives could be due to a more favourable relative spatial 
orientation of the benzene rings in these rigid compounds, although 
deeper studies would be necessary to confirm this hypothesis. 
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Table 1. IC50 (µM) values and SI indexes for combretastatin A-4, acyclic and cyclic derivatives.a 
Comp. HT-29  MCF-7  HeLa  A-549  HEK-293 SIAb SIBc SICd SIDe 
CoA4 4.2 ± 0.5 1.0 ± 0.2 2.5 ± 7 0.43 ± 0.004 25 ± 3 6 25 10 58 
15a 7 ± 2 6.2 ± 1 3.9 ±0.7 7.4 ± 0.9 1.4 ± 0.2 0.2 0.2 0.3 0.2 
15b 11 ± 2 6.0 ± 0.8 4.7 ± 0.9 8 ± 2 0.42 ± 0.05 0.04 0.07 0.09 0.09 
15c 3.2 ± 0.8 7.0 ± 0.3 5.6 ± 0.4 8.6 ± 0.8 0.26 ± 0.03 0.08 0.04 0.06 0.03 
16a 8.3 ± 0.7 11.3 ± 0.2 6.6 ± 0.8 7.2 ± 0.3 14 ± 2 4.2 5.7 0.6 2.3 
16b 12.5 ± 0.8 9.15 ± 0.05 80 ± 15 22.7 ± 0.5 52 ± 9 2.5 1.2 2.8 1.2 
16c 2.2 ± 0.4 4.75 ± 0.02 2.0 ± 0.9 4.49 ± 0.02 5.6 ± 0.3 0.8 2 1.3 0.2 
23a 13 ± 2 43 ± 2 29 ± 8 57 ± 2 64 ± 2 5 1.5 2.2 1.1 
23b 23 ± 5 50 ± 8 5.5 ± 0.9 76 ± 2 3.8 ± 0.3 0.2 0.07 0.7 0.05 
23c 37 ± 2 35 ± 3 20 ± 4 10 ± 2 26 ± 4 0.7 0.7 1.3 2.6 
24a 5.6 ± 0.9 36 ± 2 5.5 ± 0.8 19 ± 2 2.5 ± 0.3 0.4 0.07 0.4 0.1 
24b 8 ± 1.5 7.0 ± 1.2 7.6 ± 0.7 >100 6.5 ± 1.0 0.8 0.8 0.8 0.07 
24c 27 ± 2 68 ± 5 48 ± 4 >100  >100 2.7 6.8 48 1 
25a >100 44 ± 3 52 ± 6 74 ± 5 >100 1 2.3 2 1.3 
25b 45 ± 2 82 ± 2 70 ± 9 68 ± 4 85 ± 9 2 1 1.2 1.2 
25c 57 ± 5 18 ± 1 >100 21 ± 1  36 ± 5 0.6 2 0.4 1.7 
26a 7.5 ± 0.7 3.2 ± 0.6 5.0 ± 0.8 26 ± 3 6.4 ± 0.2 0.9 0.3 0.1 0.4 
26b 12 ± 2 32 ± 5 89 ± 2 25 ± 6 11 ± 2 0.4 0.8 0.8 0.4 
27a 8.4 ± 0.3 32 ± 10 6.6 ± 0.8 >100 6.4 ± 0.5 0.8 0.2 1 0.06 
27b 8.5 ± 0.6 6 ± 2 80 ± 15 54 ± 3 4.2 ± 0.3 0.5 0.7 0.05 0.08 
27c 15 ± 3 2.5 ± 0.2 2.0 ± 0.9 5.1 ± 0.2 11 ± 2 0.7 4.4 5.5 2.1 
28a >100 57 ± 3 55 ± 10 >100 45 ± 2 0.4 0.8 0.8 0.4 
28b 54 ± 9 45 ± 4 62 ± 8 >100 92 ± 7 1.7 2 1.5 0.9 
28c 35 ± 2 53 ± 2 66 ± 4 76 ± 7 32 ± 5 0.9 0.6 0.5 0.4 
29 8.0 ± 0.9 2.2 ± 0.2 1.82 ± 0,04 5.6 ± 0.5 2.4 ± 0.3 0.3 1.1 1.3 0.43 
30 >100 >100 >100 21.5 ± 0.8 >100 - - - - 
aIC50 values are expressed as the compound concentration (µM) that inhibits the cell growth by 50%. Data are the average (±SD) of three experiments. bSIA = 
IC50(HEK-293)/IC50(HT-29). cSIB = IC50(HEK-293)/IC50(MCF-7). dSIC= IC50 (HEK-293)/IC50 (HeLa). eSID= IC50 (HEK-293)/IC50 (A-549).
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Effect on the cell cycle 
The effects of compounds on the cell cycle distribution were 
evaluated in A-549 cells. Thus, cells were incubated for 20 h in the 
presence of each compound at concentrations half of their IC50 
values. Then the ADN content was measured by flow cytometry (see 
experimental section). Along with the tricyclic compounds and 
compounds 29 and 30, diolefin compounds 24a-c were also 
evaluated. These compounds were specifically selected for 
evaluation because they caused the formation of rounded cells. 
Table 2. Cell cycle distribution.a 
Comp. Conc. SubG0 G0 G1/S G2/M 
Control --- 5 69 12 13 
CoA4 50 nM 15 21  22  43  
15a 5 µM 2 87 5 4 
15b 5 µM 2 86 6 6 
15c 5 µM 6 70 10 12 
16a 5 µM 2 88 6 4 
16b 5 µM 2 89 6 3 
16c 5 µM 10 80 7 3 
23a 50 µM 13 68 10 7 
23b 50 µM 10 71 8 9 
23c 5 µM 54 44 5 3 
24a 5 µM 5 24 10 61 
24b 50 µM 5 23 11 60 
24c 50 µM 2 20 12 65 
25a 50 µM 3 84 2 4 
25b 50 µM 8 74 2 12 
25c 5 µM 9 76 4 10 
26a 25 µM 5 80 9 6 
26b 25 µM 13 71 7 8 
27a  50 µM 9 35 10 46 
27b  50 µM 11 47 12 30 
27c  5 µM 11 26 7 49 
28a  50 µM 3 65 12 19 
28b  50 µM 19 72 4 5 
28c  50 µM 7 80 6 7 
29 5 µM 32 39 14 14 
30 5 µM 15 72 8 4 
aAt least three measurements were performed in each case. 
The results shown in Table 2 indicate that the tricyclic analogues 
are unable to accumulate cells on G2/M phase to a significant extent. 
In other words, these compounds are practically devoid of 
antimitotic action. However, it is worth noting that the diolefinic 
precursors 24a-c show a noticeable percentage of cells in G2/M 
phase, with larger values than CoA4. Even though this effect is 
exerted at concentrations >100 times greater than that of CoA4, this 
suggests a certain degree of antimitotic activity of these compounds. 
Effect on endothelial cells 
It has recently been shown that CoA4 might exhibit anti-
angiogenic properties by interfering the VEGF/VEGFR-2 signalling 
pathway in endothelial cells.23 Thus, we studied the effect of our 
synthetic derivatives on the proliferation of human microvascular 
endothelial (HMEC-1) cells by MTT assay. For this study we selected 
derivatives 24a-c and 27a-c, which were the ones that accumulated 
more cells in the G2/M phase. CoA4 and Sorafenib,24 a clinically used 
VEGFR-2 inhibitor,25 were employed as positive controls. Table 3 
shows the IC50 values obtained for the tested compounds. 
Table 3. IC50 values on HMEC-1 cells and minimum active 
concentration.a 




CA-4 3.4 ± 0.4  0.003  
Sorafenib 34 ± 3 10 
24a 35 ± 2 5 
24b 32 ± 9 5 
24c 12 ± 7 0.025 
27a 39 ± 9 5 
27b 27 ± 8 1 
27c 15 ± 4 0.25 
aAt least three measurements were performed in each case. 
The data of Table 3 indicate a decrease of IC50 values for HMEC-
1 cells with the atomic number of the heteroatom present in the 
compound. Thus, the tin compounds 24c and 27c exhibit half the IC50 
value of the silicon derivatives 24a and 27a. 
Table 3 also shows the Minimum Active Concentration (MAC) at 
which the selected compounds begin to inhibit VEGF-induced 
endothelial tube formation. In order to measure this effect, HMEC-1 
cells were seeded on Matrigel and the selected derivatives 24a-c and 
27a-c, along with CoA4 and sorafenib, were immediately added at 
seriate concentrations ranging from 50 µM to 10 nM. The effect of 
the compounds on the endothelial tube formation was evaluated 
after 24 h of treatment. As an example, the photos of the inhibitory 
action of compound 24c (MAC 0.025 µM) are presented in Fig. 3. The 
most active compound is CoA4 which starts to inhibit endothelial 
tube formation at 0.003 µM. In this biological action all synthetic 
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compounds are more active than sorafenib itself. As above, the tin 
derivatives 17c and 24c proved the most active. 
 
Fig. 3. Effect of compound 24c at 5 µM (a), 0.5 µM (b), 0.05 µM 
(c) and 0.025 µM (d) concentrations. 
Inhibition of VEGFR-2 kinase activity 
The effect of the selected compounds exerted over VEGFR-2, a 
kinase receptor that plays an important role in the tumour 
angiogenic process, was also evaluated. In this assay, HMEC-1 cells 
were treated with the selected compounds for 2 hours, then VEGF 
(50 ng/mL) was added to the cell media and 30 minutes later, cells 
were lysed. Finally, phospho-VEGFR-2 was quantified from the 
lysates by ELISA analysis. The percentage of phospho-VEGFR-2 is 
expressed for each compound referred to control, which 
corresponds to 100 %. 
 
Table 4. Detection of p-VEGFR-2 by ELISA assay. 
Compound Conc. (µM) % p-VEGFR-2 
CA-4 5  74 ± 8  
Sorafenib 25 60 ± 6   
24a 25 64 ± 3   
24b 25 61 ± 3 
24c 25 52 ± 4 
27a 25 84 ± 6 
27b 25 82 ± 2 
27c 25 70 ± 4 
 
It can be deduced from Table 4 that acyclic compounds 24a-c are 
more active than cyclic derivatives 27a-c in causing the inhibition of 
the kinase action of VEGFR-2 in endothelial cells. Moreover, 
compounds 24a-c exert an inhibitory effect similar to that of 
sorafenib or the lead compound, CoA4. Again, the action of the 
compounds depends on the heteroatom they contain, the tin-
containing compounds being a little more active than the rest of the 
synthetic compounds. 
Conclusions 
A range of 23 compounds containing silicon, germanium and 
tin have been synthesized and biologically evaluated as regards 
their antiproliferative action, their effect on cell cycle, and their 
effects on endothelial tube formation and inhibition of VEGFR-
2 kinase activity. As compounds with structures inspired by that 
of combretastatin A-4, their biological actions have been 
compared with those of the natural product. Although their 
antiproliferative action and their effect on the cell cycle does 
not exceed that of CoA4, their inhibition of endothelial tube 
formation and their inhibition of VEGFR-2 phosphorylation are 
comparable to that of CoA4, particularly in the case of the tin-
containing compounds 17c and 24c, whose actions exceed 




NMR spectra (300 MHz for 1H, 75 MHz for 13C and 282 MHz for 
19F) were measured at 25°C. The signals of the deuterated 
solvent (CDCl3) were taken as the reference for 1H and 13C 
spectra. For 19F spectra (measured under 1H decoupling), δ 
values were referenced to CFCl3 (δ = 0). 13C NMR signal 
multiplicities were determined with the DEPT pulse sequence. 
Mass spectra were run in the electrospray (ESMS) mode. 
Experiments which required an inert atmosphere were carried 
out under dry Ar in a flame-dried glassware. Commercially 
available reagents were used as received. Acronyms are defined 
in the synthetic schemes. 
5-(Allyloxy)-2-bromo-4-methoxybenzaldehyde (4). Aldehyde 3 
(231 mg, 1 mmol) was dissolved under Ar in dry acetonitrile (8 
mL) and treated with anhydrous K2CO3 (207 mg, 1.5 mmol). 
Then allyl bromide (105 µL, 1.2 mmol) was added dropwise. The 
mixture was then stirred for 24 h at room temperature. After 
this time, water (10 mL) was added and the reaction mixture 
was extracted with CH2Cl2. The organic layer was washed with 
brine and then dried over anhydrous MgSO4. Removal of 
volatiles under reduced pressure gave 4, sufficiently pure for 
further use: oil; 1H NMR (300 MHz, CDCl3) δ 10.16 (1H, s), 7.41 
(1H, s), 7.05 (1H, s), 6.05 (1H, ddt, J = 17.3, 10.5, 5.5 Hz), 5.43 
(1H, ddt, J = 17.3, 1.5, 1.5 Hz), 5.32 (1H, ddt, J = 10.5, 1.5, 1.5 
Hz), 4.63 (2H, dt, J = 5.5, 1.5 Hz), 3.95 (3H, s); 13C NMR (75 MHz, 
CDCl3) δ 155.0, 147.9, 126.6, 120.6 (C), 190.9, 132.3, 115.8, 
112.2 (CH), 119.0, 70.0 (CH2), 56.6 (CH3). 
2-Bromo-5-(tert-butyldimethylsilyloxy)-4-methoxybenzaldehyde 
(5). Aldehyde 3 (231 mg, 1 mmol) was dissolved under Ar in dry 
THF (6 mL), cooled to 0°C and treated with TBSCl (226 mg, 1.5 
mmol) and imidazole (204 mg, 3 mmol). The mixture was then 
ARTICLE Journal Name 
8 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
Please do not adjust margins 
Please do not adjust margins 
stirred for 16 h at room temperature. After this time, water (10 
mL) was added and the reaction mixture was extracted with 
EtOAc. The organic layer was washed with satd NaHCO3, then 
with brine and finally dried over anhydrous MgSO4. Removal of 
volatiles under reduced pressure gave an oily residue which was 
chromatographed on silica gel (elution with hexane-EtOAc 4:1). 
This gave 5, sufficiently pure for further use (259 mg, 75%): oil; 
1H NMR (300 MHz, CDCl3) δ 10.14 (1H, s), 7.39 (1H, s), 7.03 (1H, 
s), 3.88 (3H, s), 0.98 (9H, s), 0.16 (6H, s); 13C NMR (75 MHz, 
CDCl3) δ 156.9, 145.1, 126.9, 120.5, 18.5 (C), 190.9, 120.6, 116.1 
(CH), 56.1, 25.7 (x 3), −4.5 (x 2) (CH3). 
(Z)-1-(5-Allyloxy-2-bromo-4-methoxystyryl)-2-bromo-3,4,5-
trimethoxybenzene (6). A solution of triphenyl (2-bromo-3,4,5-
trimethoxybenzyl) phosphonium bromide 1 (300 mg, 0.5 mmol) 
in dry THF (8 mL) was cooled to 0°C and treated under Ar with 
KOtBu (62 mg, 0.55 mmol). The mixture is then stirred for 30 
min. at 0 °C. A solution of the appropriate aldehyde 4 (0.4 mmol) 
in dry THF (8 mL) is then added dropwise, and the mixture is 
stirred at room temperature for 16 h. After this time, water (30 
mL) was added and the reaction mixture was extracted with 
EtOAc. The organic layer was washed with brine and finally 
dried over anhydrous MgSO4. Removal of volatiles under 
reduced pressure gave an oily residue which was 
chromatographed on silica gel (elution with hexane-EtOAc 9:1). 
The desired olefination product was obtained as an off-white 
solid in 93% yield: oil; 1H NMR (300 MHz, CDCl3) δ 7.01 (1H, s), 
6.68 (1H, d, J = 11.8 Hz), 6.59 (1H, d, J = 11.8 Hz), 6.53 (1H, s), 
6.40 (1H, s), 5.76 (1H, ddt, J = 17.3, 10.5, 5.5 Hz), 5.16 (1H, ddt, 
J = 17.3, 1.5, 1.5 Hz), 5.11 (1H, ddt, J = 10.5, 1.5, 1.5 Hz), 4.18 
(2H, dt, J = 5.5, 1.5 Hz), 3.89 (3H, s), 3.84 (3H, s), 3.83 (3H, s), 
3.49 (3H, s); 13C NMR (75 MHz, CDCl3) δ 152.5, 151.1, 149.4, 
146.9, 142.4, 132.9, 128.9, 114.8, 110.3 (C), 132.5, 130.3, 130.1, 
115.3, 115.2, 109.8 (CH), 118.4, 69.8 (CH2), 61.2, 61.1, 56.2, 56.0 
(CH3). 
(Z)-[4-Bromo-5-(2-bromo-3,4,5-trimethoxystyryl)-2-methoxy-
phenoxy](tert-butyl)dimethylsilane (7). Prepared as above in 
82% yield from phosphonium salt 1 and aldehyde 5: off-white 
gum; 1H NMR (300 MHz, CDCl3) δ 7.01 (1H, s), 6.65 (1H, d, J = 
11.8 Hz), 6.62 (1H, d, J = 11.8 Hz), 6.52 (1H, s), 6.39 (1H, s), 3.89 
(3H, s), 3.85 (3H, s), 3.78 (3H, s), 3.51 (3H, s), 0.84 (9H, s), −0.08 
(6H, s); 13C NMR (75 MHz, CDCl3) δ 152.4, 151.3, 151.1, 144.2, 
142.4, 133.0, 129.4, 115.2, 110.3, 18.4 (C), 130.3 (x 2), 122.7, 
115.8, 109.7 (CH), 61.2, 61.1, 56.0, 55.9, 25.6 (x 3), −4.8 (x 2) 
(CH3). 
(Z)-4-Bromo-5-(2-bromo-3,4,5-trimethoxystyryl)-2-methoxy-
phenol (8). Compound 7 (118 mg, 0.2 mmol) was dissolved 
under Ar in dry THF (6 mL) and cooled to 0°C. A solution of 1M 
TBAF in THF (0.3 mL, 0.3 mmol) was slowly added dropwise. The 
mixture is then stirred at room temperature for 1 h. After this 
time, satd aq NaHCO3 (10 mL) was added and the reaction 
mixture was extracted with EtOAc. The organic layer was 
washed three times with brine and finally dried over anhydrous 
MgSO4. Compound 8 was obtained in almost quantitative yield, 
sufficiently pure for further use: off-white gum; 1H NMR (300 
MHz, CDCl3) δ 7.02 (1H, s), 6.68 (1H, d, J = 11.8 Hz), 6.67 (1H, s), 
6.62 (1H, d, J = 11.8 Hz), 6.44 (1H, s), 3.90 (3H, s), 3.86 (6H, s), 
3.48 (3H, s) (OH proton not detected); 13C NMR (75 MHz, CDCl3) 
δ 152.2, 151.0, 146.6, 144.7, 142.6, 132.3, 130.1, 113.4, 110.7 
(C), 130.2, 130.0, 116.4, 114.6, 109.7 (CH), 61.3, 61.1, 56.3, 56.0 
(CH3). 
(Z)-2-Bromo-1-[2-bromo-4-methoxy-5-(methoxymethoxy)styryl]- 
3,4,5-trimethoxybenzene (9): Compound 8 (47 mg, 0.1 mmol) 
was dissolved under Ar in dry CH2Cl2 (3 mL), cooled to 0°C and 
treated with DIPEA (0.15 mmol, 26 µL) and MOM chloride (0.12 
mmol, 9 µL). The mixture was then stirred at room temperature 
for 12 h. After this time, the solvent was removed under 
reduced pressure and EtOAc (10 mL) was added. The organic 
layer was then successively washed with 2M NaOH, water and 
brine and finally dried over anhydrous MgSO4. Compound 9 was 
obtained in almost quantitative yield, sufficiently pure for 
further use: off-white gum; 1H NMR (300 MHz, CDCl3) δ 7.04 
(1H, s), 6.83 (1H, s), 6.68 (1H, d, J = 11.8 Hz), 6.65 (1H, d, J = 11.8 
Hz), 6.42 (1H, s), 4.85 (2H, s), 3.89 (3H, s), 3.85 (3H, s), 3.84 (3H, 
s), 3.51 (3H, s), 3.26 (3H, s). 
2-Bromo-3,4,5-trimethoxy-1-vinylbenzene (10). A solution of 
methyl triphenylphosphonium iodide (1 mmol, 404 mg) in dry 
THF (4 mL) was treated under an inert atmosphere with 2.5M n-
BuLi (1 mmol, 0.4 mL). The mixture was then stirred for 20 min. 
at room temperature. A solution of 2-bromo-3,4,5-trimethoxy-
benzaldehyde (1 mmol) in dry THF (3 mL) is then added 
dropwise, and the mixture is stirred at room temperature for 2 
h. After this time, satd aq NH4Cl (5 mL) was added and the 
reaction mixture was extracted with CH2Cl2. The organic layer 
was washed three times with brine and finally dried over 
anhydrous MgSO4. Removal of volatiles under reduced pressure 
gave an oily residue which was chromatographed on silica gel 
(elution with hexane-EtOAc 9:1) to yield 10 (74%): oil; 1H NMR 
(300 MHz, CDCl3) δ 7.04 (1H, dd, J = 17.3, 10.8 Hz), 6.89 (1H, s), 
5.60 (1H, dd, J = 17.3, 1 Hz), 5.31 (1H, dd, J = 10.8, 1 Hz), 3.88 
(9H, s); 13C NMR (75 MHz, CDCl3) δ 152.8, 150.9, 143.1, 133.3, 
110.6 (C), 136.0, 105.3 (CH), 116.0 (CH2), 61.3, 61.0, 56.2 (CH3). 
2-Bromo-3,4-dimethoxy-5-(triphenylmethyl)oxy-1-vinylbenzene 
(11). Aldehyde 3 (2.16 mmol, 500 mg) was dissolved in dry 
CH2Cl2 (12 mL), cooled to 0°C and treated with triethylamine 
(5.40 mmol, 752 µL) and triphenylmethyl chloride (4.30 mmol, 
1.2 g). The mixture was then stirred for 14 h at room 
temperature. After this time, satd aq NH4Cl (5 mL) was added 
and the reaction mixture was extracted with CH2Cl2. The organic 
layer was washed three times with brine and finally dried over 
anhydrous MgSO4. Removal of volatiles under reduced 
pressure gave an oily residue of the tritylated aldehyde, which 
was then subjected to Wittig methylenation under the 
conditions described above to yield 11 (60%): yellowish gum; 1H 
NMR (300 MHz, CDCl3) δ 7.53-7.48 (6H, m), 7.35-7.25 (9H, m), 
6.88 (1H, s), 6.85 (1H, s), 6.78 (1H, dd, J = 17.3, 10.8 Hz), 5.03 
(1H, dd, J = 10.8, 1 Hz), 4.98 (1H, dd, J = 17.3, 1 Hz), 3.62 (3H, s); 
13C NMR (75 MHz, CDCl3) δ 152.8, 145.2, 144.0 (x 3), 128.7, 
116.0, 91.6 (C), 135.2, 129.3 (x 6), 127.7 (x 6), 127.5 (x 3), 119.9, 
115.8 (CH), 114.4 (CH2), 56.1 (CH3). 
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Dimethyl bis(2,3,4-trimethoxy-6-vinylphenyl)silane (15a). 
Compound 10 (2.1 mmol) was dissolved under Ar in dry THF (7 
mL) and cooled to −78°C. A 2.5M solution of n-BuLi in hexane 
(0.84 mL, 2.1 mmol) was added dropwise and the mixture was 
stirred at the same temperature for 30 min. Then, Me2SiCl2 (1 
mmol) dissolved in dry THF (2 mL) was added dropwise with 
stirring, and the mixture was allowed to reach room 
temperature. The stirring was maintained for 12 h. After this 
time, satd aq NH4Cl (5 mL) was added and the reaction mixture 
was extracted with CH2Cl2. The organic layer was washed three 
times with brine and finally dried over anhydrous MgSO4. 
Removal of volatiles under reduced pressure gave an oily 
residue which was chromatographed on silica gel (elution with 
hexane-Et2O 95:5) to yield 15a (40%): off-white gum; 1H NMR 
(300 MHz, CDCl3) δ 7.05 (2H, dd, J = 17.3, 10.8 Hz), 6.78 (2H, s), 
5.40 (2H, dd, J = 17.3, 1.5 Hz), 5.08 (2H, dd, J = 10.8, 1.5 Hz), 3.87 
(6H, s), 3.81 (6H, s), 3.50 (6H, s), 0.60 (6H, s); 13C NMR (75 MHz, 
CDCl3) δ 158.0 (x 2), 154.3 (x 2), 141.1 (x 2), 139.9 (x 2), 124.6 (x 
2) (C), 139.2 (x 2), 106.0 (x 2) (CH), 114.2 (x 2) (CH2), 60.6 (x 2), 
60.1 (x 2), 55.9 (x 2), 5.0 (x 2) (CH3); HR ESMS m/z 467.1873 
(M+Na+). Calcd. for C24H32NaO6Si, 467.1866. 
Dimethyl bis(2,3,4-trimethoxy-6-vinylphenyl)germane (15b). 
Compound 10 and Me2GeCl2 (1 mmol) were allowed to react 
under the same reaction conditions as above for 15a. Work-up 
gave an oily residue which was chromatographed on silica gel 
(elution with hexane-Et2O 95:5) to yield 15b (43%): off-white 
gum; 1H NMR (300 MHz, CDCl3) δ 6.86 (2H, dd, J = 17.3, 10.8 Hz), 
6.73 (2H, s), 5.33 (2H, dd, J = 17.3, 1.5 Hz), 5.00 (2H, dd, J = 10.8, 
1.5 Hz), 3.80 (6H, s), 3.75 (6H, s), 3.52 (6H, s), 0.67 (6H, s); 13C 
NMR (75 MHz, CDCl3) δ 157.0 (x 2), 154.0 (x 2), 141.2 (x 2), 139.2 
(x 2), 127.1 (x 2) (C), 138.6 (x 2), 105.6 (x 2) (CH), 114.1 (x 2) 
(CH2), 60.7 (x 2), 60.5 (x 2), 55.9 (x 2), 5.1 (x 2) (CH3); HR ESMS 
m/z 513.1315 (M+Na+). Calcd. for C24H3274GeNaO6, 513.1308. 
Dimethyl bis(2,3,4-trimethoxy-6-vinylphenyl)stannane (15c). 
Compound 10 and Me2SnCl2 (1 mmol) were allowed to react 
under the same reaction conditions as above for 15a. Work-up 
gave an oily residue which was chromatographed on silica gel 
(elution with hexane-Et2O 95:5) to yield 15c (57%): off-white 
gum; 1H NMR (300 MHz, CDCl3) δ 6.90 (2H, s), 6.84 (2H, dd, J = 
17.3, 10.8 Hz), 5.48 (2H, dd, J = 17.3, 1.5 Hz), 5.10 (2H, dd, J = 
10.8, 1.5 Hz), 3.88 (6H, s), 3.82 (6H, s), 3.65 (6H, s), 0.55 (6H, s); 
13C NMR (75 MHz, CDCl3) δ 157.2 (x 2), 154.4 (x 2), 140.7 (x 2), 
140.5 (x 2), 128.8 (x 2) (C), 139.4 (x 2), 105.0 (x 2) (CH), 114.0 (x 
2) (CH2), 60.7 (x 2), 60.6 (x 2), 56.0 (x 2), −2.6 (x 2) (CH3); HR 
ESMS m/z 559.1124 (M+Na+). Calcd. for C24H32NaO6120Sn, 
559.1118. 
2,3,4,6,7,8-Hexamethoxy-5,5-dimethyl-5H-dibenzo[b,f]silepine 
(16a). The second-generation Hoveyda-Grubbs ruthenium 
catalyst (0.01 mmol, 6.3 mg) was disolved under Ar in dry, 
deoxygenated toluene (40 mL). A solution of diolefin 15a (0.1 
mmol) in dry, deoxygenated toluene (27 mL) was then added 
dropwise. The mixture was then heated at reflux until 
consumption of the starting material (TLC monitoring). After the 
required time, the volatiles were removed under reduced 
pressure and the oily residue was chromatographed on silica gel 
(elution with hexane-Et2O 95:5) to yield 16a (86%): off-white 
solid, mp 200-202°C; 1H NMR (300 MHz, CDCl3) δ 6.84 (2H, s), 
6.67 (2H, s), 3.87 (6H, s), 3.85 (6H, s), 3.84 (6H, s), 0.58 (6H, s); 
13C NMR (75 MHz, CDCl3) δ 157.6 (x 2), 153.8 (x 2), 142.3 (x 2), 
137.6 (x 2), 123.5 (x 2) (C), 133.0 (x 2), 109.4 (x 2) (CH), 61.4 (x 
2), 60.8 (x 2), 56.0 (x 2), 1.0 (x 2) (CH3); HR ESMS m/z 439.1554 
(M+Na+). Calcd. for C22H28NaO6Si, 439.1553. 
2,3,4,6,7,8-Hexamethoxy-5,5-dimethyl-5H-
dibenzo[b,f]germepine (16b). Prepared from diolefin 15b under 
the same reaction conditions as for 16a. Chromatography on 
silica gel (elution with hexane-Et2O 95:5) gave 16b (90%): off-
white solid, mp 202-204°C; 1H NMR (300 MHz, CDCl3) δ 6.76 (2H, 
s), 6.65 (2H, s), 3.86 (6H, s), 3.85 (6H, s), 3.84 (6H, s), 0.74 (6H, 
s); 13C NMR (75 MHz, CDCl3) δ 156.7 (x 2), 153.6 (x 2), 142.1 (x 
2), 137.1 (x 2), 126.0 (x 2) (C), 133.1 (x 2), 109.4 (x 2) (CH), 61.3 
(x 2), 60.8 (x 2), 56.0 (x 2), 1.3 (x 2) (CH3); HR ESMS m/z 485.0976 
(M+Na+). Calcd. for C22H2874GeNaO6, 485.0995. 
2,3,4,6,7,8-Hexamethoxy-5,5-dimethyl-5H-dibenzo[b,f]stannepine 
(16c). Prepared from diolefin 15c under the same reaction 
conditions as for 16a. Chromatography on silica gel (elution with 
hexane-Et2O 95:5) gave 16c (21%): off-white solid, mp 173-175 
°C; 1H NMR (300 MHz, CDCl3) δ 6.66 (2H, s), 6.65 (2H, s), 3.86 
(6H, s), 3.85 (6H, s), 3.84 (6H, s), 0.57 (6H, s); 13C NMR (75 MHz, 
CDCl3) δ 156.9 (x 2), 154.0 (x 2), 141.2 (x 2), 139.0 (x 2), 127.7 (x 
2) (C), 133.4 (x 2), 110.3 (x 2) (CH), 61.1 (x 2), 60.8 (x 2), 56.1 (x 
2), −6.4 (x 2) (CH3); HR ESMS m/z 531.0818 (M+Na+). Calcd. for 
C22H28NaO6120Sn, 531.0805. 
1-Bromo-4,5-dimethoxy-2-vinylbenzene (20). Prepared in 85% 
yield by means of Wittig methylenation of aldehyde 17 as 
described for the synthesis of 10: oil; 1H NMR (300 MHz, CDCl3) 
δ 7.03 (1H, s), 6.99 (1H, s), 6.97 (1H, dd, J = 17.3, 10.8 Hz), 5.58 
(1H, dd, J = 17.3, 1 Hz), 5.26 (1H, dd, J = 10.8, 1 Hz), 3.89 (3H, s), 
3.86 (3H, s); 13C NMR (75 MHz, CDCl3) δ 149.5, 148.7, 129.6, 
114.4 (C), 135.5, 115.4, 108.8 (CH), 114.7 (CH2), 56.3, 56.1 (CH3). 
5-Bromo-6-vinylbenzo[d][1,3]dioxole (21). Prepared in 79% 
yield by means of Wittig methylenation of aldehyde 18 as 
described for the synthesis of 10: oil; 1H NMR (300 MHz, CDCl3) 
δ 7.03 (1H, s), 6.99 (1H, s), 6.98 (1H, dd, J = 17.3, 10.8 Hz), 5.97 
(2H, s), 5.55 (1H, dd, J = 17.3, 1 Hz), 5.26 (1H, dd, J = 10.8, 1 Hz); 
13C NMR (75 MHz, CDCl3) δ 148.2, 147.8, 131.0, 114.8 (C), 135.6, 
112.7, 106.1 (CH), 115.1, 101.9 (CH2). 
1-Bromo-4-fluoro-2-vinylbenzene (22). Prepared in 47% yield by 
means of Wittig methylenation of aldehyde 19 as described for 
the synthesis of 10: oil; 1H NMR (300 MHz, CDCl3) δ 7.50 (1H, dd, 
J = 8.8, 5.5 Hz), 7.25 (1H, dd, J = 9.7, 3 Hz), 7.00 (1H, ddd, J = 
17.3, 10.9, 1.5 Hz), 6.86 (1H, ddd, J = 8.8, 7.8, 3 Hz), 5.70 (1H, 
dd, J = 17.3, 1 Hz), 5.42 (1H, dd, J = 10.9, 1 Hz); 13C NMR (75 MHz, 
CDCl3) δ 162.3 (center point of doublet, 1JC−F = 245 Hz), 139.3 
(doublet, 3JC−F = 7.5 Hz), 117.8 (doublet, 4JC−F = 3 Hz) (C), 135.2 
(doublet, 4JC−F = 2 Hz), 134.2 (doublet, 3JC−F = 8 Hz), 116.5 
(doublet, 2JC−F = 22.5 Hz), 113.6 (doublet, 2JC−F = 23 Hz) (CH), 
118.0 (CH2); 19F NMR (282 MHz, CDCl3) δ −113.4. 
Bis(4,5-dimethoxy-2-vinylphenyl)dimethylsilane (23a). 
Prepared in 36% yield from 20 under the same reaction 
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conditions as in the synthesis of 15a: off-white gum; 1H NMR 
(300 MHz, CDCl3) δ 7.11 (2H, s), 6.98 (2H, s), 6.80 (2H, dd, J = 
17.3, 10.8 Hz), 5.47 (2H, dd, J = 17.3, 1.2 Hz), 5.04 (2H, dd, J = 
10.8, 1.2 Hz), 3.92 (6H, s), 3.83 (6H, s), 0.60 (6H, s); 13C NMR (75 
MHz, CDCl3) δ 150.2 (x 2), 148.2 (x 2), 137.5 (x 2), 128.7 (x 2) (C), 
137.7 (x 2), 117.5 (x 2), 108.4 (x 2) (CH), 113.1 (x 2) (CH2), 56.0 
(x 2), 55.8 (x 2), 0.4 (x 2) (CH3). 
Bis(4,5-dimethoxy-2-vinylphenyl)dimethylgermane (23b). 
Prepared in 34% yield from 20 under the same reaction 
conditions as in the synthesis of 15b: off-white gum; 1H NMR 
(300 MHz, CDCl3) δ 7.15 (2H, s), 6.88 (2H, s), 6.77 (2H, dd, J = 
17.3, 10.8 Hz), 5.52 (2H, dd, J = 17.3, 1.2 Hz), 5.08 (2H, dd, J = 
10.8, 1.2 Hz), 3.92 (6H, s), 3.80 (6H, s), 0.72 (6H, s); 13C NMR (75 
MHz, CDCl3) δ 149.9 (x 2), 148.5 (x 2), 136.4 (x 2), 131.0 (x 2) (C), 
137.6 (x 2), 116.7 (x 2), 108.2 (x 2) (CH), 113.0 (x 2) (CH2), 55.9 
(x 2), 55.8 (x 2), 0.3 (x 2) (CH3). 
Bis(4,5-dimethoxy-2-vinylphenyl)dimethylstannane (23c). 
Prepared in 50% yield from 20 under the same reaction 
conditions as in the synthesis of 15c: off-white gum; 1H NMR 
(300 MHz, CDCl3) δ 7.18 (2H, s), 6.88 (2H, s), 6.71 (2H, dd, J = 
17.3, 10.8 Hz), 5.55 (2H, dd, J = 17.3, 1.2 Hz), 5.14 (2H, dd, J = 
10.8, 1.2 Hz), 3.92 (6H, s), 3.79 (6H, s), 0.57 (6H, s); 13C NMR (75 
MHz, CDCl3) δ 150.0 (x 2), 148.6 (x 2), 137.9 (x 2), 132.5 (x 2) (C), 
139.2 (x 2), 118.7 (x 2), 106.0 (x 2) (CH), 113.3 (x 2) (CH2), 55.9 
(x 2), 55.8 (x 2), −6.9 (x 2) (CH3). 
Dimethyl bis(6-vinylbenzo[d][1,3]dioxol-5-yl)silane (24a). Prepared 
in 36% yield from 21 under the same reaction conditions as in 
the synthesis of 15a: off-white gum; 1H NMR (300 MHz, CDCl3) 
δ 7.07 (2H, s), 6.97 (2H, s), 6.77 (2H, dd, J = 17.3, 10.8 Hz), 5.96 
(4H, s), 5.43 (2H, dd, J = 17.3, 1.2 Hz), 5.02 (2H, dd, J = 10.8, 1.2 
Hz), 0.55 (6H, s); 13C NMR (75 MHz, CDCl3) δ 149.2 (x 2), 147.2 (x 
2), 138.9 (x 2), 130.4 (x 2) (C), 137.3 (x 2), 113.9 (x 2), 106.0 (x 2) 
(CH), 113.5, 101.0 (x 2) (CH2), 0.3 (x 2) (CH3). 
Dimethyl bis(6-vinylbenzo[d][1,3]dioxol-5-yl)germane (24b). 
Prepared in 41% yield from 21 under the same reaction 
conditions as in the synthesis of 15b: off-white gum; 1H NMR 
(300 MHz, CDCl3) δ 7.12 (2H, s), 6.88 (2H, s), 6.73 (2H, dd, J = 
17.3, 10.8 Hz), 5.96 (4H, s), 5.48 (2H, dd, J = 17.3, 1.2 Hz), 5.07 
(2H, dd, J = 10.8, 1.2 Hz), 0.68 (6H, s); 13C NMR (75 MHz, CDCl3) 
δ 149.0 (x 2), 147.3 (x 2), 137.7 (x 2), 132.6 (x 2) (C), 137.3 (x 2), 
113.3 (x 2), 105.8 (x 2) (CH), 113.5, 101.0 (x 2) (CH2), 0.2 (x 2) 
(CH3). 
Dimethyl bis(6-vinylbenzo[d][1,3]dioxol-5-yl)stannane (24c). 
Prepared in 47% yield from 21 under the same reaction 
conditions as in the synthesis of 15c: off-white gum; 1H NMR 
(300 MHz, CDCl3) δ 7.15 (2H, s), 6.87 (2H, s), 6.67 (2H, dd, J = 
17.3, 10.8 Hz), 5.95 (4H, s), 5.53 (2H, dd, J = 17.3, 1 Hz), 5.13 (2H, 
dd, J = 10.8, 1 Hz), 0.55 (6H, s); 13C NMR (75 MHz, CDCl3) δ 149.2 
(x 2), 147.4 (x 2), 139.1 (x 2), 134.1 (x 2) (C), 138.8 (x 2), 113.8 (x 
2), 105.8 (x 2) (CH), 115.3, 101.0 (x 2) (CH2), −6.8 (x 2) (CH3). 
Bis(4-fluoro-2-vinylphenyl)dimethylsilane (25a). Prepared in 
20% yield from 22 under the same reaction conditions as in the 
synthesis of 15a: oil; 1H NMR (300 MHz, CDCl3) δ 7.47 (2H, dd, J 
= 8.3, 6.5 Hz), 7.22 (2H, dd, J = 10.7, 2.5 Hz), 6.97 (2H, td, J = 8.3, 
2.5 Hz), 6.75 (2H, ddd, J = 17.3, 10.8, 1.7 Hz), 5.55 (2H, dd, J = 
17.3, 1 Hz), 5.13 (2H, dd, J = 10.8, 1 Hz), 0.58 (6H, s); 13C NMR 
(75 MHz, CDCl3) δ 164.6 (x 2, center point of doublet, 1JC−F = 
246.5 Hz), 146.6 (x 2, doublet, 3JC−F = 7 Hz), 132.2 (x 2, doublet, 
4JC−F = 3 Hz) (C), 137.0 (x 2, doublet, 3JC−F = 7.5 Hz), 136.9 (x 2, 
doublet, 4JC−F = 2 Hz), 114.2 (x 2, doublet, 2JC−F = 19.5 Hz), 112.4 
(x 2, doublet, 2JC−F = 20.5 Hz) (CH), 116.3 (x 2) (CH2), 0.0 (x 2) 
(CH3); 19F NMR (282 MHz, CDCl3) δ −112.4. 
Bis(4-fluoro-2-vinylphenyl)dimethylgermane (25b). Prepared 
in 22% yield from 22 under the same reaction conditions as in 
the synthesis of 15b: oil; 1H NMR (300 MHz, CDCl3) δ 7.37 (2H, 
dd, J = 8.3, 6.5 Hz), 7.27 (2H, dd, J = 10.7, 2.5 Hz), 6.95 (2H, td, J 
= 8.3, 2.5 Hz), 6.73 (2H, ddd, J = 17.2, 10.8, 1.7 Hz), 5.59 (2H, dd, 
J = 17.2, 1 Hz), 5.18 (2H, dd, J = 10.8, 1 Hz), 0.70 (6H, s); 13C NMR 
(75 MHz, CDCl3) δ 164.1 (x 2, center point of doublet, 1JC−F = 246 
Hz), 145.7 (x 2, doublet, 3JC−F = 6.7 Hz), 134.3 (x 2, doublet, 4JC−F 
= 3.3 Hz) (C), 136.8 (x 2, doublet, 4JC−F = 2.7 Hz), 136.0 (x 2, 
doublet, 3JC−F = 7.7 Hz), 114.4 (x 2, doublet, 2JC−F = 20 Hz), 112.3 
(x 2, doublet, 2JC−F = 20.5 Hz) (CH), 116.4 (x 2) (CH2), −0.2 (x 2) 
(CH3); 19F NMR (282 MHz, CDCl3) δ −113.4. 
Bis(4-fluoro-2-vinylphenyl)dimethylstannane (25c). Prepared 
in 25% yield from 22 under the same reaction conditions as in 
the synthesis of 15c: oil; 1H NMR (300 MHz, CDCl3) δ 7.35 (2H, 
dd, J = 8, 6.5 Hz), 7.30 (2H, dd, J = 10.7, 2.5 Hz), 6.95 (2H, td, J = 
8, 2.5 Hz), 6.70 (2H, ddd, J = 17.2, 10.8, 1.7 Hz), 5.63 (2H, dd, J = 
17.2, 1 Hz), 5.26 (2H, dd, J = 10.8, 1 Hz), 0.57 (6H, s); 13C NMR 
(75 MHz, CDCl3) δ 164.2 (x 2, center point of doublet, 1JC−F = 245 
Hz), 147.2 (x 2, doublet, 3JC−F = 6.7 Hz), 135.8 (x 2, doublet, 4JC−F 
= 3.5 Hz) (C), 138.3 (x 2, doublet, 4JC−F = 2.6 Hz), 138.2 (x 2, 
doublet, 3JC−F = 7 Hz), 114.6 (x 2, doublet, 2JC−F = 19.5 Hz), 112.2 
(x 2, doublet, 2JC−F = 20.5 Hz) (CH), 116.7 (x 2) (CH2), −7.2 (x 2) 
(CH3); 19F NMR (282 MHz, CDCl3) δ −113.3. 
2,3,7,8-Tetramethoxy-5,5-dimethyl-5H-dibenzo[b,f]silepine 
(26a). Prepared from diolefin 23a under the same reaction 
conditions as in the synthesis of 16a. Chromatography on silica 
gel (elution with hexane-Et2O 95:5) gave 26a (90%): off-white 
solid, mp 200-202 ºC; 1H NMR (300 MHz, CDCl3) δ 7.01 (2H, s), 
6.89 (2H, s), 6.85 (2H, s), 3.92 (6H, s), 3.88 (6H, s), 0.48 (6H, s); 
13C NMR (75 MHz, CDCl3) δ 149.6 (x 2), 149.0 (x 2), 135.3 (x 2), 
129.0 (x 2) (C), 131.7 (x 2), 114.6 (x 2), 112.8 (x 2) (CH), 56.1 (x 
2), 55.9 (x 2), −4.1 (x 2) (CH3); HR ESMS m/z 379.1347 (M+Na+). 
Calcd. for C20H24NaO4Si, 379.1342. 
2,3,7,8-Tetramethoxy-5,5-dimethyl-5H-
dibenzo[b,f]germepine (26b). Prepared from diolefin 23b 
under the same reaction conditions as in the synthesis of 16a. 
Chromatography on silica gel (elution with hexane-Et2O 95:5) 
gave 26b (78%): off-white solid, mp 203-205 ºC; 1H NMR (300 
MHz, CDCl3) δ 6.92 (2H, s), 6.88 (2H, s), 6.78 (2H, s), 3.91 (6H, s), 
3.87 (6H, s), 0.60 (6H, s); 13C NMR (75 MHz, CDCl3) δ 149.2 (x 2), 
149.0 (x 2), 134.7 (x 2), 131.3 (x 2) (C), 132.0 (x 2), 114.2 (x 2), 
112.7 (x 2) (CH), 56.1 (x 2), 56.0 (x 2), −4.7 (x 2) (CH3); HR ESMS 
m/z 403.0969 (M+H+). Calcd. for C20H2574GeO4, 403.0965. 
Silepine 27a. Prepared from diolefin 24a under the same 
reaction conditions as in the synthesis of 16a. Chromatography 
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on silica gel (elution with hexane-Et2O 95:5) gave 27a (86%): oil; 
1H NMR (300 MHz, CDCl3) δ 6.98 (2H, s), 6.85 (2H, s), 6.78 (2H, 
s), 5.93 (4H, s), 0.43 (6H, s); 13C NMR (75 MHz, CDCl3) δ 148.6 (x 
2), 147.8 (x 2), 136.4 (x 2), 130.5 (x 2) (C), 131.7 (x 2), 111.4 (x 
2), 110.0 (x 2) (CH), 101.0 (CH2), −4.2 (x 2) (CH3); HR ESMS m/z 
325.0886 (M+H+). Calcd. for C18H17O4Si, 325.0896. 
Germepine 27b. Prepared from diolefin 24b under the same 
reaction conditions as in the synthesis of 16a. Chromatography 
on silica gel (elution with hexane-Et2O 95:5) gave 27b (80%): oil; 
1H NMR (300 MHz, CDCl3) δ 6.90 (2H, s), 6.83 (2H, s), 6.71 (2H, 
s), 5.92 (4H, s), 0.56 (6H, s); 13C NMR (75 MHz, CDCl3) δ 148.3 (x 
2), 147.8 (x 2), 135.6 (x 2), 132.8 (x 2) (C), 131.9 (x 2), 111.0 (x 
2), 109.8 (x 2) (CH), 101.0 (CH2), −4.8 (x 2) (CH3); HR ESMS m/z 
371.0358 (M+H+). Calcd. for C18H1774GeO4, 371.0340. 
Stannepine 27c. Prepared from diolefin 24c under the same 
reaction conditions as in the synthesis of 16a. Chromatography 
on silica gel (elution with hexane-Et2O 95:5) gave 27c (23%): oil; 
1H NMR (300 MHz, CDCl3) δ 6.90 (2H, s), 6.83 (2H, s), 6.71 (2H, 
s), 5.92 (4H, s), 0.56 (6H, s); 13C NMR (75 MHz, CDCl3) δ 148.4 (x 
2), 147.5 (x 2), 137.5 (x 2), 134.3 (x 2) (C), 133.1 (x 2), 113.2 (x 
2), 109.7 (x 2) (CH), 100.9 (CH2), −11.2 (x 2) (CH3); HR ESMS m/z 
417.0110 (M+H+). Calcd. for C18H17O4120Sn, 417.0149. 
2,8-Difluoro-5,5-dimethyl-5H-dibenzo[b,f]silepine (28a). 
Prepared from diolefin 25a under the same reaction conditions 
as in the synthesis of 16a. Chromatography on silica gel (elution 
with hexane-Et2O 95:5) gave 28a (80%): off-white solid, mp 102-
104°C; 1H NMR (300 MHz, CDCl3) δ 7.55-7.50 (2H, m), 7.10-7.00 
(4H, m), 6.92 (2H, s), 0.48 (6H, s); 13C NMR (75 MHz, CDCl3) δ 
163.7 (x 2, center point of doublet, 1JC−F = 246 Hz), 143.4 (x 2, 
doublet, 3JC−F = 7 Hz), 133.2 (x 2, doublet, 4JC−F = 3 Hz) (C), 134.6 
(x 2, doublet, 3JC−F = 7.5 Hz), 133.1 (x 2, doublet, 4JC−F = 2 Hz), 
116.2 (x 2, doublet, 2JC−F = 20 Hz), 114.9 (x 2, doublet, 2JC−F = 20 
Hz) (CH), −4.2 (x 2) (CH3); 19F NMR (282 MHz, CDCl3) δ −113.3. 
2,8-Difluoro-5,5-dimethyl-5H-dibenzo[b,f]germepine (28b). 
Prepared from diolefin 25b under the same reaction conditions 
as in the synthesis of 16a. Chromatography on silica gel (elution 
with hexane-Et2O 95:5) gave 28b (70%): off-white solid, mp 98-
100°C; 1H NMR (300 MHz, CDCl3) δ 7.45-7.40 (2H, m), 7.10-7.00 
(4H, m), 6.86 (2H, s), 0.60 (6H, s); 13C NMR (75 MHz, CDCl3) δ 
163.4 (x 2, center point of doublet, 1JC−F = 245 Hz), 143.0 (x 2, 
doublet, 3JC−F = 6.7 Hz), 135.3 (x 2, doublet, 4JC−F = 3.5 Hz) (C), 
133.8 (x 2, doublet, 3JC−F = 7.5 Hz), 133.2 (x 2, doublet, 4JC−F = 2.5 
Hz), 116.2 (x 2, doublet, 2JC−F = 20 Hz), 114.9 (x 2, doublet, 2JC−F = 
19.5 Hz) (CH), −4.8 (x 2) (CH3); 19F NMR (282 MHz, CDCl3) δ 
−114.2. 
2,8-Difluoro-5,5-dimethyl-5H-dibenzo[b,f]stannepine (28c). 
Prepared from diolefin 25c under the same reaction conditions 
as in the synthesis of 16a. Chromatography on silica gel (elution 
with hexane-Et2O 95:5) gave 28c (28%): off-white solid, mp 96-
98°C; 1H NMR (300 MHz, CDCl3) δ 7.40 (2H, dd, J = 8, 6.5 Hz), 
7.03 (2H, dd, J = 10.8, 2.5 Hz), 6.98 (2H, td, J = 8.5, 2.5 Hz), 6.86 
(2H, s), 0.45 (6H, s); 13C NMR (75 MHz, CDCl3) δ 163.5 (x 2, center 
point of doublet, 1JC−F = 245 Hz), 145.1 (x 2, doublet, 3JC−F = 6.5 
Hz), 136.9 (x 2, doublet, 4JC−F = 3.5 Hz) (C), 136.3 (x 2, doublet, 
3JC−F = 7.5 Hz), 134.0 (x 2, doublet, 4JC−F = 2.7 Hz), 116.0 (x 2, 
doublet, 2JC−F = 20 Hz), 114.7 (x 2, doublet, 2JC−F = 19 Hz) (CH), 
−11.2 (x 2) (CH3); 19F NMR (282 MHz, CDCl3) δ −114.1. 
Biological studies. Materials and methods 
Cell culture 
Cell culture media were purchased from Gibco (Grand Island, 
NY). Fetal bovine serum (FBS) was a product of Harlan-Seralab 
(Belton, U.K.). Supplements and other chemicals not listed in this 
section were obtained from Sigma Chemical Co. (St. Louis, MO). 
Plastics for cell culture were supplied by Thermo Scientific BioLite. All 
tested compounds were dissolved in DMSO at a concentration of 20 
μM and stored at -20°C until use. 
HT-29, MCF-7, HeLa and HEK-293 cell lines were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) containing glucose 
(1g/L), glutamine (2 mM), penicillin (50 IU/mL), streptomycin (50 
μg/mL), and amphotericin B (1.25 μg/mL), supplemented with 10% 
FBS. HMEC-1 cell line was maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) low glucose, glutamine (2 mM), penicillin (50 
IU/mL), streptomycin (50 μg/mL), and amphotericin B (1.25 μg/mL), 
supplemented with 10% FBS. 
MTT assay 
A total of 5 × 103 HT-29, MCF-7, HeLa or HEK-293 cells in a total 
volume of 100 μL of their respective growth media were incubated 
with serial dilutions of the tested compounds. The 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma 
Chemical Co.) dye reduction assay in 96-well microplates was used, 
as previously described [26]. After 2 days of incubation (37 °C, 5% 
CO2 in a humid atmosphere), 10 μL of MTT (5 mg/mL in phosphate-
buffered saline, PBS) was added to each well, and the plate was 
incubated for a further 3 h (37 °C). The supernatant was discarded 
and replaced by 100 µL of DMSO to dissolve formazan crystals. The 
absorbance was then read at 490 nm by spectrophotometry. For all 
concentrations of compound, cell viability was expressed as the 
percentage of the ratio between the mean absorbance of treated 
cells and the mean absorbance of untreated cells. Three independent 
experiments were performed, and the IC50 values (i.e., concentration 
half inhibiting cell proliferation) were graphically determined. 
Cell cycle analysis 
Progression of the cell cycle was analysed by means of flow 
cytometry with propidium iodide. After incubation with compounds 
for 24 h, A549 cells were fixed, treated with RNase and stained with 
propidium iodide following instructions of BD CycletestTM DNA Kit. 
Analysis was performed with a BD AccuriTM C6 flow cytometer. 
Tube formation inhibition assay 
Wells of a 96-well μ-plate for angiogenesis were coated with 12 
μL of Matrigel (10 mg/mL, BD Biosciences) at 4ºC. After gelatinization 
at 37ºC for 30 min, HMEC-1 cells were seeded at 2 x 104 cells/well in 
25 μL of culture medium on top of the Matrigel and were incubated 
30 min at 37ºC while are attached. Then, compounds were added 
dissolved in 25 μL of culture medium and after 20 h of incubation at 
37ºC, tube destruction was evaluated and photographed.  
Phospho-VEGFR2 quantification by ELISA 
 
HMEC-1 cells were seeded at 5·105 cells/well in 6-well plates and 
once they were at 80% of their confluency, they were starved with 
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medium containing 0.1% of FBS for 24 h. Then, cells were incubated 
with the corresponding compounds for 2 hours and next cells were 
stimulated with 50 ng/ml of Recombinant VEGF-165 for 30 minutes 
at 37ºC. After that, lysates were collected, protein quantification was 
carried out by Bradford test and, then, and phospho-VEGFR2 was 
quantified using PathScan® Phospho-VEGFR2(Tyr1175) Sandwich 
ELISA Kit according to the manufacturer’s instructions. 
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